-
Mashup Score: 4Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future - 10 month(s) ago
Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory multiple myeloma (MM) have been poor because of a dearth of effective treatment options. However, the advent of chimeric antigen receptor (CAR) T-cell and T-cell redirecting bispecific antibody (BsAb) therapies has led to unprecedented response rates and durations of response in heavily relapsed/refractory (R/R) populations. Currently, two B-cell maturation antigen (BCMA)–directed CAR T-cell therapies (idecabtagene vicleucel and ciltacabtagene autoleucel) as well as one BCMA/CD3 BsAb (teclistamab) have been approved for late-line (greater than four previous lines) R/R MM in the United States. The purpose of this review is to analyze the recent data for these approved therapies as well as provide an overview of other related CAR T-cell and BsAb therapies under development, including non–BCMA-targeting agents. We review efficacy and safety considerations, with particular focus on cytokine re
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial - 11 month(s) ago
Key Points. The VITAL study of birtamimab in newly diagnosed AL amyloidosis was discontinued early per futility analysisBirtamimab improved post hoc all-cause m
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects - 11 month(s) ago
Selinexor (KPT-330) is a small molecule inhibitor of XPO1, which mediates the transport of tumor suppressor proteins, oncogene messenger RNAs, and oth…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Internal Medicine: Update & Intensive Review 2023 - 29th Annual - 1 year(s) ago
ACCME, ANCC & International EACCME Credits, MOC Points, Virtual Conference
Source: www.eventleaf.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
An Illinois doctor who consulted with a patient’s treating physician but never actually saw the patient himself can’t escape a medical malpractice claim, a state appeals court ruled.
Source: MedscapeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
THE TAKEAWAYIn 1998, McLaughlin et al1 demonstrated that nearly half of patients with relapsed and refractory indolent B-cell lymphoma responded to single-agent anti-CD20 monoclonal antibody treatment with rituximab, with a median progression-free survival exceeding 12 months. The impact of this trial on patients with B-cell lymphomas cannot be overstated, as it directly led to the first US Food…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Editorial Roster | Journal of Clinical Oncology - 1 year(s) ago
Editor-in-Chief Jonathan W. Friedberg, MD, University of Rochester, Rochester, NY, USASenior Deputy Editor Kathy D. Miller, MD, IUSCCC, Indianapolis, IN, USADeputy Editors Bruce G. Haffty, MD, Rutgers Cancer Institute, New Brunswick, NJ, USA Alexia Iasonos, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USAAssociate Editors Smita Bhatia, MD, MPH, FASCO University of Alabama,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Risk model - iStopMM - 1 year(s) ago
Iceland Screens Treats or Prevents Multiple Myeloma
Source: iStopMMCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Registration - 1 year(s) ago
Back to Main Entrance Registration for the face-to-face congress in Paris Early Registration until March 15, 2023 Standard Registration from March 16, 2023 and
Source: The 9th COMy World CongressCategories: Hem/Oncs, Latest HeadlinesTweet
Excellent overview on Bispecfics and CAR-T cell treatment in #myeloma by @DrSarahHolstein Shakira Grant and @tanyawildes 👍🏻 in @JCO_ASCO #mmsm Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future https://t.co/d4fFgxFj5x